Cytokinetics appoints Edward M. Kay to board
Dr. Kaye has served as Interim Chief Executive Officer of Sarepta since 2015 and as the SVP, Chief Medical Officer since 2011.
Prior to joining Sarepta, he was employed by Genzyme Corporation for ten years, holding various senior management positions, the most recent of which was Group Vice President of Clinical Development.
Previously, Dr. Kaye served as Chief of Biochemical Genetics at Children's Hospital of Philadelphia and Associate Professor of Neurology and Pediatrics at the University Of Pennsylvania School Of Medicine.
He serves as a Neurological Consultant at the Children's Hospital of Boston and is on the editorial boards of a number of medical journals.
Dr. Kaye is also a member of several scientific advisory boards, including United Leukodystrophy Foundation, Spinal Muscular Atrophy Foundation, CureCMD, CureDuchenne and Prize4Life.
Dr. Kaye received his medical education and pediatric training at Loyola University Stritch School of Medicine and University Hospital, child neurology training at Boston City Hospital, Boston University, and completed his training as a neurochemical research fellow at Bedford VA Hospital, Boston University. ■
LATEST MOVES FROM California
- Banc of California names Doug Bowers as CEO
- Reed's appoints Stefan Freeman as interim CEO
- Heron Therapeutics appoints Robert E. Hoffman as CFO
- Penumbra appoints Bridget O'Rourke to board
- Adverum Biotechnologies adds Richard N. Spivey to board
More inside POST
AIG board: No cash bonus for CEO Companies